Peptide5

Peptide5

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

H-VDCFLSRPTEKT-OH

H-Val-Asp-Cys-Phe-Leu-Ser-Arg-Pro-Thr-Glu-Lys-Thr-OH

12

95.24%

C₆₀H₉₈N₁₆O₂₀S

1395.57

Synthetic

Powder

Peptide5, also known as connexin43 mimetic peptide 5, was designed to bind to extracellular regions of the connexin43 (Cx43) protein, and is a blocker of Connexin43 hemichannels. Connexin43 hemichannels in spinal cord astrocytes are implicated in the maintenance of neuropathic pain following peripheral nerve injury and Peptide 5 can reduce swelling, astrogliosis, neuroinflammation and neuronal cell death following spinal cord injury. Peptide5 exhibits analgesic effects in models of neuropathic pain.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual:Handling and Storage of Synthetic Peptides

• O'Carroll et al (2008) Connexin 43 mimetic peptides reduce swelling, astrogliosis and neuronal cell death after spinal cord injury. Cell.Commun.Adhes. 15 27 PMID: 18649176
• Mao et al (2017) Characterisation of Peptide5 systemic administration for treating traumatic spinal cord injured rats. Exp.Brain.Res. 235 3033 PMID: 28725925
• Tonkin et al (2017) Attenuation of mechanical pain hypersensitivity by treatment with Peptide5, a connexin-43 mimetic peptide, involves inhibition of NLRP3 inflammasome in nerve-injured mice. Exp.Neurol. 300 1 PMID: 29055716

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.